Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
110 stopped studies mapped to Malignant Solid Neoplasm and descendants · 95% state a reason
Over the 110 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04438382 | Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With… | Phase 2 | terminated | Jun 18, 2020 | ECOG-ACRIN Cancer Research Group | Slow accrual | Enrollment / accrual |
| NCT05629689 | A Study to Evaluate GEH200520/GEH200521 (18F) Safety and Tolerability When Used for PET… | Phase 1 | terminated | Nov 29, 2022 | GE Healthcare | GE-269-001 Part A in cancer patients was completed. Part B was significantly delayed due to slow… | Enrollment / accrual |
| NCT05477784 | Cancer Parenting Program for the Enhancement of the Quality of Life of Patients With…(EC-PC) | N/A | terminated | Jul 28, 2022 | University of Washington | Enrollment rates to the trial were lower than projected and anticipated. | Enrollment / accrual |
| NCT00801151 | Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer | Phase 1 | terminated | Dec 3, 2008 | Institut Claudius Regaud | not stated | Not stated |
| NCT04111172 | A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma | Phase 2 | suspended | Oct 1, 2019 | Thomas Jefferson University | Protocol is with FDA review, waiting for funding to be released | Funding |
| NCT06549478 | Biology-Guided Radiation Therapy for the Treatment of Patients With Bone Metastases | Phase 1 | suspended | Aug 12, 2024 | City of Hope Medical Center | Budget Issue | Funding |
| NCT06573294 | Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors | Phase 1 | terminated | Aug 27, 2024 | Genmab | Genmab has decided to terminate the GEN1057 program due to marginal anti-tumor activity not… | Other (stated, no rule matched) |
| NCT06500377 | Comparing the Impact of Four Types of Meditation Practices for Relaxation in Cancer… | N/A | suspended | Jul 15, 2024 | City of Hope Medical Center | Accrual Goal Met | Enrollment / accrual |
| NCT06581211 | Aromatherapy Oil Associated for Managing Anxiety and Pain During Bone Marrow Biopsy… | N/A | suspended | Sep 3, 2024 | City of Hope Medical Center | Accrual goal met | Enrollment / accrual |
| NCT06438588 | Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on… | N/A | terminated | Jun 3, 2024 | Mayo Clinic | Low accrual | Enrollment / accrual |
| NCT06620302 | Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment… | Phase 1 / Phase 2 | suspended | Oct 1, 2024 | Children's Oncology Group | Unacceptable Toxicity | Safety / toxicity |
| NCT06202066 | Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients… | Phase 2 | suspended | Jan 11, 2024 | Roswell Park Cancer Institute | pending protocol changes | Other (stated, no rule matched) |
| NCT04840589 | Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid… | Phase 1 | suspended | Apr 12, 2021 | National Cancer Institute (NCI) | Other - Pending amendment. | Other (stated, no rule matched) |
| NCT05791448 | AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver… | Phase 1 | suspended | Mar 30, 2023 | University of Southern California | Pending protocol amendment | Other (stated, no rule matched) |
| NCT04605614 | 64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression | Phase 1 | withdrawn | Oct 28, 2020 | City of Hope Medical Center | slow accruals | Enrollment / accrual |
| NCT05101213 | Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered… | Phase 1 | terminated | Nov 1, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT06391775 | Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors… | Phase 1 / Phase 2 | terminated | Apr 30, 2024 | Genmab | Terminated due to strategic decision | Sponsor / business decision |
| NCT04552704 | CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid… | Phase 1 / Phase 2 | terminated | Sep 17, 2020 | Tianhong Li | Terminated early by the Sponsor due to business reason. | Sponsor / business decision |
| NCT02962661 | Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients… | Phase 1 | suspended | Nov 11, 2016 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT03065387 | Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With… | Phase 1 | terminated | Feb 27, 2017 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT07449481 | A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in… | Phase 2 | withdrawn | Mar 4, 2026 | Tianjin Medical University Cancer Institute and Hospital | Following an evaluation by the investigator, the study has been terminated due to exceptional… | Investigator |
| NCT05967533 | The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With… | Phase 1 | suspended | Aug 1, 2023 | University of California, Davis | For internal interim analysis | Efficacy / futility |
| NCT05101356 | A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab… | Phase 1 / Phase 2 | suspended | Nov 1, 2021 | University of California, Davis | Drugs unavailable | Other (stated, no rule matched) |
| NCT04500548 | Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in… | Phase 1 | withdrawn | Aug 5, 2020 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT04630431 | Understanding Challenges, Behavioral Patterns, and Preferences Toward Participation in… | N/A | terminated | Nov 16, 2020 | Mayo Clinic | Low/slow accrual | Enrollment / accrual |
| NCT04168528 | Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT | Phase 1 / Phase 2 | terminated | Nov 19, 2019 | Universitair Ziekenhuis Brussel | Delay in recruitment | Enrollment / accrual |
| NCT07082257 | Precision Performance Status Compared With ECOG Performance Status | — | terminated | Jul 24, 2025 | University of Southern California | Study is not progressing towards scientific goals | Other (stated, no rule matched) |
| NCT04588246 | Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to… | Phase 3 | terminated | Oct 19, 2020 | NRG Oncology | Inadequate accrual rate | Enrollment / accrual |
| NCT04955808 | Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate,… | — | suspended | Jul 9, 2021 | National Cancer Institute (NCI) | Due to slow accrual on this trial, we will allow sites time to work on close-out procedures and… | Enrollment / accrual |
| NCT04902040 | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced… | Phase 1 / Phase 2 | terminated | May 26, 2021 | M.D. Anderson Cancer Center | PI requested. | Other (stated, no rule matched) |
| NCT06630325 | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced… | Phase 2 | terminated | Oct 8, 2024 | OHSU Knight Cancer Institute | Loss of support. | Other (stated, no rule matched) |
| NCT05660421 | Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising… | Phase 2 | withdrawn | Dec 21, 2022 | Douglas Johnson | Lack of accrual and funding | Enrollment / accrual |
| NCT04387071 | CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers… | Phase 1 / Phase 2 | terminated | May 13, 2020 | University of Southern California | Study drug no longer available | Other (stated, no rule matched) |
| NCT04241835 | A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With… | Phase 1 | terminated | Jan 27, 2020 | Epizyme, Inc. | Ipsen decided to discontinue all active tazemetostat clinical trials. | Other (stated, no rule matched) |
| NCT05012124 | Using Technology to Optimize Collaborative Care Management of Depression in Urban and… | N/A | terminated | Aug 19, 2021 | University of Washington | Study closed to accrual before meeting accrual goal due to enrollment challenges and end of funding. | Enrollment / accrual |
| NCT05091632 | Assessment of Verbal Comprehension and Cognitive Processes in Patients Admitted to the… | — | suspended | Oct 25, 2021 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT03420963 | Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and… | Phase 1 | terminated | Feb 5, 2018 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT04789668 | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases | Phase 1 / Phase 2 | terminated | Mar 9, 2021 | M.D. Anderson Cancer Center | Insufficient accrual | Enrollment / accrual |
| NCT04785287 | Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the… | Phase 1 / Phase 2 | terminated | Mar 5, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT06771921 | A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors | Phase 1 / Phase 2 | terminated | Jan 13, 2025 | Genmab | The sponsor has made the decision to terminate further development of GEN1078 based on emerging… | Safety / toxicity |
| NCT02408861 | Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory… | Phase 1 | terminated | Apr 6, 2015 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT06508034 | Probiotics for the Prevention of Immunotherapy Induced Colitis in Patients Receiving… | N/A | suspended | Jul 18, 2024 | Mayo Clinic | Change in funding status | Funding |
| NCT04379518 | Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients | Phase 1 / Phase 2 | terminated | May 7, 2020 | Roswell Park Cancer Institute | Low accrual | Enrollment / accrual |
| NCT06626256 | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable… | Phase 1 | withdrawn | Oct 3, 2024 | City of Hope Medical Center | no resource | Other (stated, no rule matched) |
| NCT05844306 | RefleXion PET/CT Imaging Performance in Patients With Various Malignancies | N/A | suspended | May 6, 2023 | City of Hope Medical Center | goals met | Other (stated, no rule matched) |
| NCT05859464 | A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors | Phase 1 | terminated | May 16, 2023 | Zai Lab (Hong Kong), Ltd. | Sponsor Decision | Sponsor / business decision |
| NCT04372641 | Testing the Safety of CB-5339 in Patients With Cancer | Phase 1 | withdrawn | May 4, 2020 | National Cancer Institute (NCI) | Other - Clinical development of the agent has been discontinued | Other (stated, no rule matched) |
| NCT04557709 | Major Complication Rate in Cancer Patients With Neutropenic Fever Potentially Eligible… | — | withdrawn | Sep 22, 2020 | M.D. Anderson Cancer Center | 0 participants | Other (stated, no rule matched) |
| NCT00507572 | Collection of Outcomes Data for Pregnant Patients With Cancer | — | terminated | Jul 26, 2007 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT03579446 | Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer | Early Phase 1 | terminated | Jul 6, 2018 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 1 hour agoSource updated Sep 29, 2026source: clinicaltrials